Innovative Medicine Database

Disclaimer: The website is intended solely for facilitating non-profit research and development in relation to medical and healthcare related policies. (Last update on: 24 Oct 2024)

Unlock The Innovative Medicines Of Tomorrow

The Drug Database comprises a wide range of innovative medicines that have been approved by drug administration agencies around the globe while are not approved or financed in Hong Kong, and that showed satisfying efficacy and acceptable safety in phase 2/3 clinical trials. This database provides extensive information to accommodate most of research and discovery needs and spans multiple therapeutic areas.
{{ disease.title }}
Active Substance
Brand Name
Drug Class
Phase of Study
HK Drug Office Status
FDA
EMA
NMPA
Active Substance
Abbreviations

Anti-IL: Anti-interleukin; JAK: Janus kinase; PARP: Poly ADP-ribose polymerase; NMDA: N-methyl-D-aspartate; NMBA: Neuromuscular Blocking Agent; GABA: Gamma-aminobutyric acid; S1P: Sphingosine-1-phosphate; TNF: Tumor Necrosis factor; TLR: Toll-like receptor.

This project is funded by the UGC Research Impact Fund (RIF)(reference number: R7007-22)
Copyright © 2024 Li Ka Shing Faculty of Medicine, The University of Hong Kong. All Rights Reserved.
Web Design by YSD